ReviewCureus2024
Effectiveness of Tranexamic Acid in Trauma Patients: A Systematic Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tranexamic acid can reduce blood loss and improve visibility in otological surgeries: a systematic review and meta-analysis of randomised controlled trials.The Journal of laryngology and otology · 2025Pooled it
- A worldwide cross-sectional survey seeks the current global practice patterns on perioperative management in elective shoulder replacement surgery.JSES international · 2026Article
- Efficacy and Safety of Tranexamic Acid in Pediatric Trauma: A Systematic Review and Meta-Analysis.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Mortality Benefit of Tranexamic Acid for Hemorrhage With Concurrent Traumatic Brain Injury: Outcomes From a Prospective Cohort Study in a High-Trauma, Prolonged Care Setting.World journal of surgery · 2026Article
- Local delivery of tranexamic acid for hemorrhage control in trauma: a narrative review.Frontiers in drug delivery · 2026Review
- Does TXA reduce total volume of 24-hour blood products transfused in post-traumatic hemorrhage in a resource-constrained setting:Secondary analysis of a prospective cohort trauma study in South Africa.International journal of emergency medicine · 2025Article
- Exploiting the Molecular Properties of Fibrinogen to Control Bleeding Following Vascular Injury.International journal of molecular sciences · 2025Review
- A newly developed, easy-to-use prehospital drug-derived score compared with three conventional scores: A prospective multicenter study.European journal of clinical investigation · 2025Article
- Targeting Inflammation After Hemorrhagic Shock as a Molecular and Experimental Journey to Improve Outcomes: A Review.Cureus · 2025Review
- Navigating Hemorrhagic Shock: Biomarkers, Therapies, and Challenges in Clinical Care.Biomedicines · 2024Review
- Hemobilia: A Narrative Review of Current Diagnostic Techniques and Emerging Management Strategies.Cureus · 2024Review
- Review
- Exploring Aspirin's Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence.Cureus · 2024Review
- The Prediction and Treatment of Bleeding Esophageal Varices in the Artificial Intelligence Era: A Review.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tranexamic acid (TXA), a fibrinolytic agent, effectively inhibits plasminogen activation, thereby reducing fibrinolysis and hemorrhage. This study focused on its application in trauma patients undergoing emergency surgery, a critical area due to trauma's significant role in mortality. Our investigation involved a meticulous screening of randomized controlled trials from databases including Scopus, PubMed, Web of Science, and Cochrane. The findings indicate that TXA intervention is promising in enhancing outcomes for trauma patients. However, the drug's effectiveness may vary based on the specific nature of the medical condition. In summary, robust evidence suggests that TXA can diminish blood loss, lower transfusion rates, reduce complications, and improve hemoglobin and hematocrit levels in surgical patients. Consequently, TXA should be considered a crucial medication, readily available to mitigate morbidity and mortality in surgical settings. Future research should explore factors influencing TXA's effectiveness in traumatic brain injury cases and across a broad spectrum of surgical scenarios in diverse patient populations. This would further guide clinicians in refining and optimizing the use of TXA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.